Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment

Article Hematology

Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy

Remy Dulery et al.

Summary: Age >= 70 years, relapsed/refractory lymphoma, and recent administration of anti-CD20 therapy are risk factors for prolonged length of in-hospital stay and death for lymphoma patients hospitalized for Covid-19.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Robert Spiera et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

Antonio Gallo et al.

Summary: Multiple sclerosis patients treated with ocrelizumab showed a significantly blunted humoral response to the BNT162b2-mRNA vaccine, highlighting the need for further research to confirm and optimize vaccination strategies for this population.

NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Review Hematology

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

Abi Vijenthira et al.

Summary: The study found that patients receiving anti-CD20 therapy have poor responses to all types of vaccines, especially during treatment and at least 6 months post-treatment, with significantly lower SC rates compared to healthy and disease control groups. As time progresses, response to vaccination gradually improves, but even 12 months post-therapy, it may not reach the level of healthy controls.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology